Your browser doesn't support javascript.
loading
Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development.
Regev, Arie; Avigan, Mark I; Kiazand, Alexandre; Vierling, John M; Lewis, James H; Omokaro, Stephanie O; Di Bisceglie, Adrian M; Fontana, Robert J; Bonkovsky, Herbert L; Freston, James W; Uetrecht, Jack P; Miller, Ethan D; Pehlivanov, Nonko D; Haque, Syed Asif; Harrison, Melanie J; Kullak-Ublick, Gerd A; Li, Hewei; Patel, Niti N; Patwardhan, Meenal; Price, Karen D; Watkins, Paul B; Chalasani, Naga P.
Afiliação
  • Regev A; Eli Lilly, Indianapolis, IN, USA. Electronic address: regev_arie@lilly.com.
  • Avigan MI; US Food and Drug Administration, Silver Spring, MD, USA.
  • Kiazand A; AstraZeneca Pharmaceuticals, Gaithersburg, MD, USA.
  • Vierling JM; Baylor College of Medicine, Houston, TX, USA.
  • Lewis JH; Georgetown University, Washington, DC, USA.
  • Omokaro SO; US Food and Drug Administration, Silver Spring, MD, USA.
  • Di Bisceglie AM; Saint Louis University, St. Louis, MO, USA.
  • Fontana RJ; University of Michigan, Ann Arbor, MI, USA.
  • Bonkovsky HL; Wake Forest University, Winston-Salem, NC, USA.
  • Freston JW; University of Connecticut, Stamford, CT, USA.
  • Uetrecht JP; University of Toronto, Toronto, ON, Canada.
  • Miller ED; MD Anderson, Houston, TX, USA.
  • Pehlivanov ND; Janssen Pharmaceuticals, Titusville, NJ, USA.
  • Haque SA; AstraZeneca Pharmaceuticals, Gaithersburg, MD, USA.
  • Harrison MJ; Bristol-Myers Squibb, Lawrenceville, NJ, USA.
  • Kullak-Ublick GA; Novartis, Basel, Switzerland, and University Hospital Zurich, University of Zurich, Zurich, Switzerland.
  • Li H; Bristol-Myers Squibb, Lawrenceville, NJ, USA.
  • Patel NN; Takeda, Cambridge, MA, USA.
  • Patwardhan M; AbbVie, Chicago, IL, USA.
  • Price KD; Bristol-Myers Squibb, New Brunswick, NJ, USA.
  • Watkins PB; University of North Carolina, Chapel Hill, NC, USA.
  • Chalasani NP; Indiana University School of Medicine, Indianapolis, IN, USA. Electronic address: nchalasa@iu.edu.
J Autoimmun ; 114: 102514, 2020 11.
Article em En | MEDLINE | ID: mdl-32768244
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Temas: ECOS / Aspectos_gerais Bases de dados: MEDLINE Assunto principal: Suscetibilidade a Doenças / Doença Hepática Induzida por Substâncias e Drogas / Inibidores de Checkpoint Imunológico Tipo de estudo: Diagnostic_studies / Guideline / Prognostic_studies Limite: Animals / Humans Idioma: En Revista: J Autoimmun Assunto da revista: ALERGIA E IMUNOLOGIA Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Temas: ECOS / Aspectos_gerais Bases de dados: MEDLINE Assunto principal: Suscetibilidade a Doenças / Doença Hepática Induzida por Substâncias e Drogas / Inibidores de Checkpoint Imunológico Tipo de estudo: Diagnostic_studies / Guideline / Prognostic_studies Limite: Animals / Humans Idioma: En Revista: J Autoimmun Assunto da revista: ALERGIA E IMUNOLOGIA Ano de publicação: 2020 Tipo de documento: Article